Jean-Paul Clozel, Idorsia CEO (AP Images)
Idorsia claims PhIII win for hypertension drug at center of $230M J&J deal
Months after earning its first approval, Idorsia is back with a Phase III win for a different, J&J-partnered drug.
The Swiss biotech said aprocitentan, its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
